文献速递乳腺癌

强化烷化剂化疗用于携带同源重组缺陷的寡转移性乳腺癌患者:随机III期OLIGO研究的主要结局

Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.
PubMed 文献 · Eur J Cancer · 2024-10-20

OLIGO研究纳入75例HER2阴性、携带同源重组缺陷(HRD)、≤3个远处转移且对3周期常规剂量化疗(CDCT)有良好反应的寡转移性乳腺癌(OMBC)患者,1:1随机接受强化烷化剂化疗(IACT)或继续CDCT。IACT组中位无事件生存期28个月 vs CDCT组25个月(HR 0.78,95%CI 0.42-1.42),中位总生存期67个月 vs 36个月(HR 0.74,95%CI 0.37-1.48)。作者结论为IACT较CDCT未改善结局,OMBC的最佳治疗需进一步研究。

要点

  • 全研究人群中位总生存期远超5年,但IACT较CDCT未改善无事件生存期与总生存期。
  • IACT组中位无事件生存期28个月 vs CDCT组25个月,HR 0.78(95%CI 0.42-1.42)。
  • IACT组中位总生存期67个月 vs CDCT组36个月,HR 0.74(95%CI 0.37-1.48)。

核心结论

  • IACT较CDCT未改善携带研究定义HRD的OMBC患者的结局,OMBC的最佳治疗需进一步研究。

研究设计与样本

  • 随机III期OLIGO研究,75例HER2阴性、携带HRD、≤3个远处转移、有病理学远处转移证据且对3周期CDCT有良好反应的OMBC患者,1:1随机分入IACT组(n=36)或CDCT组(n=39)。
  • IACT包括1个动员疗程后接2周期mini-CTC(卡铂、塞替派和环磷酰胺),并予外周血祖细胞回输支持;主要终点为无事件生存期(EFS),次要终点包括总生存期(OS)、生活质量和安全性。

主要发现

  • 23例(31%)为激素受体阳性疾病,52例(69%)为三阴性疾病。
  • IACT组中位EFS为28个月(95%CI 21-未达到[NR])vs CDCT组25个月(95%CI 14-NR),复发或死亡HR 0.78(95%CI 0.42-1.42)。
  • IACT组中位OS为67个月(95%CI 37-NR)vs CDCT组36个月(95%CI 26-NR),HR 0.74(95%CI 0.37-1.48)。

临床怎么用

  • 原文未据此给出推荐;作者结论为IACT较CDCT未改善携带研究定义HRD的OMBC患者的结局,OMBC的最佳治疗需进一步研究。

局限性

  • 原文结论指出OMBC的最佳治疗需进一步研究(requires further study)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oligometastatic breast cancer (OMBC) is a clinical entity with a prospect of long-term survival, but uncertainty remains on its optimal treatment. We studied whether intensified alkylating chemotherapy (IACT) improves long-term outcome compared to conventional-dose chemotherapy (CDCT) as part of a multimodality approach for patients with OMBC harboring homologous recombination deficiency (HRD). PATIENTS AND METHODS: Eligible patients had HER2-negative OMBC, harboring HRD, with ≤ 3 distant metastases, pathologic proof of distant disease and a favorable response to three cycles CDCT. Participants were randomized 1:1 to continue with either CDCT or IACT. IACT consisted of one mobilization course followed by two cycles of mini-CTC (carboplatin, thiotepa and cyclophosphamide) supported by peripheral blood progenitor cell reinfusion. Primary outcome was event-free survival (EFS). Secondary endpoints included overall survival (OS), quality of life and safety. RESULTS: Seventy-five patients were randomized to either IACT (n = 36) or CDCT (n = 39). Twenty-three (31 %) patients had hormone receptor-positive disease and 52 (69 %) had triple-negative disease. Median EFS in the IACT-group was 28 months (95 % confidence interval [CI] 21-not reached [NR]) versus 25 months (95 %CI 14-NR) in the CDCT-group (hazard ratio [HR] for recurrence or death 0.78, 95 %CI 0.42-1.42). Median OS was 67 months (95 %CI 37-NR) in the IACT-group and 36 (95 %CI 26-NR) in the CDCT-group (HR 0.74, 95 %CI 0.37-1.48). CONCLUSIONS: The entire study population experienced long-term survival, with median OS well over five years. IACT compared to CDCT did not improve outcome in patients with OMBC harboring study-defined HRD. The optimal therapy for patients with OMBC requires further study. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01646034.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. van Ommen-Nijhof A, Steenbruggen TG, Wiersma TG, et al. Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study. Eur J Cancer. 2024. PMID: 39489924. doi:10.1016/j.ejca.2024.115083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。